Alpha-Lipoic Acid in Breast Cancer Patients

NACompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

March 1, 2019

Primary Completion Date

October 30, 2020

Study Completion Date

October 30, 2020

Conditions
Breast CancerChemotherapeutic Toxicity
Interventions
DIETARY_SUPPLEMENT

Alpha-lipoic acid Plus Chemotherapy (doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by taxol)

600 mg Alpha-lipoic acid daily (an antioxidant that's in many foods, and it's made naturally in the investigator's bodies) with four cycles of doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by weekly taxol for 12 weeks..

OTHER

Placebo Plus Chemotherapy (doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by taxol)

Placebo with four cycles of doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by weekly taxol for 12 weeks.

Trial Locations (1)

Unknown

Tanta Oncology Center, Tanta

All Listed Sponsors
lead

Damanhour University

OTHER

NCT03908528 - Alpha-Lipoic Acid in Breast Cancer Patients | Biotech Hunter | Biotech Hunter